SPRUCE BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $98.22M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | $-6.68 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $-8.94 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | $-3.50 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | – | $-0.32 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $600.00K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | During market hours | $1.60M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | During market hours | – | – | – |
Press releases
Announcements Spruce Biosciences filed with the SEC
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.2 to Form 8-K
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Material agreement · Agreement terminated · Results of operations · Executive or director change · EX-99.1 to Form 8-K
Long -Term Data Presented at the 22 nd Annual WORLD Symposium
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Conference Call April 15, 2025 Javier Szwarcberg, M.D., M.P.H., CEO Samir Gharib, M.B.A., President & CFO Kirk Ways, M.D., Ph.D., CMO
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
Results of operations · EX-99 to Form 8-K
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K